首页> 外文OA文献 >Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors

【2h】

Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors

机译：用EGFR-酪氨酸激酶抑制剂治疗EGFR-突变体非小细胞肺癌患者的表达及其临床意义

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Kimio Yonesaka; Eiji Iwama; Hidetoshi Hayashi; Shinichiro Suzuki; Ryoji Kato; Satomi Watanabe; Takayuki Takahama; Junko Tanizaki; Kaoru Tanaka; Masayuki Takeda; Kazuko Sakai; Koichi Azuma; Yasutaka Chiba; Shinji Atagi; Kazuto Nishio; Isamu Okamoto; Kazuhiko Nakagawa;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors [J] . Kimio Yonesaka, Eiji Iwama, Hidetoshi Hayashi, Scientific reports. . 2019,第1期

机译：用EGFR-酪氨酸激酶抑制剂治疗EGFR-突变体非小细胞肺癌患者的表达及其临床意义
2. Clinical impact of amphiregulin expression in patients with epidermal growth factor receptor (EGFR) wild-type nonsmall cell lung cancer treated with EGFR-tyrosine kinase inhibitors [J] . Myung Hee Chang MD, Hee Kyung Ahn MD, Jeeyun Lee MD PhD, Cancer . 2011,第1期

机译：EGFR-酪氨酸激酶抑制剂治疗表皮生长因子受体（EGFR）野生型非小细胞肺癌患者双调蛋白表达的临床影响
3. The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors [J] . Lee Ji Yun, Ku Bo Mi, Lim Sung Hee, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2015,第6期

机译：EGFR酪氨酸激酶抑制剂治疗EGFR突变型非小细胞肺癌患者的BIM缺失多态性及其临床意义
4. Association between tumor heterogeneity and progression-free survival in non-small cell lung cancer patients with EGFR mutations undergoing tyrosine kinase inhibitors therapy [C] . Jiangdian Song, Di Dong, Yanqi Huang, Annual International Conference of the IEEE Engineering in Medicine and Biology Society . 2016

机译：接受酪氨酸激酶抑制剂治疗的EGFR突变非小细胞肺癌患者肿瘤异质性与无进展生存的关系
5. Predictive Biomarkers of the Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treating Advanced Non-small Cell Lung Cancer: A Systematic Review of Randomized Controlled Trials [D] . Yang, Zuyao. 2014

机译：表皮生长因子受体酪氨酸激酶抑制剂治疗晚期非小细胞肺癌疗效的预测生物标志物：随机对照试验的系统评价。
6. Intrinsic Resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance [O] . Eric Santoni-Rugiu, Linea C. Melchior, Edyta M. Urbanska, 2019

机译：EGFR突变型非小细胞肺癌中对EGFR酪氨酸激酶抑制剂的内在抗性：获得性抗性的异同
7. HER3 ligand heregulin expression and clinical implication in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors [O] . K. Yonesaka, E. Iwama, H. Hayashi, 2019

机译：HER3配体在富尔酪氨酸激酶抑制剂治疗表皮生长因子受体（EGFR） - 矫正非小细胞肺癌患者中表达和临床意义

Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors

著录项

引文网络

相似文献

相关主题

期刊订阅